FIELD: chemistry.
SUBSTANCE: invention relates to a novel crystalline form of (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]-pyrimidin-1-yl)-1-pyrrolidinyl)-2-propen-1-one, which has an antitumor effect. Crystalline form is characterized by a powder X-ray diffraction containing characteristic peaks at diffraction angles (2θ±0.2°), selected from 9.5°, 14.3°, 16.7°, 19.1°, 20.8°, 21.9° and 25.2°, and endothermic peak at approximately 166 °C, obtained by the method of differential scanning calorimetry.
EFFECT: new crystalline form of antitumor compound is proposed.
5 cl, 6 dwg, 2 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW SALT OF CONDENSED PYRIMIDINE COMPOUND AND CRYSTAL THEREOF | 2016 |
|
RU2702660C2 |
| CRYSTAL FORM OF THE PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE | 2017 |
|
RU2793759C2 |
| AZABICYCLIC COMPOUND CRYSTALS | 2016 |
|
RU2697521C2 |
| BENZOXAZOLE DERIVATIVE CRYSTAL | 2019 |
|
RU2787767C2 |
| NEW CRYSTALS OF URACIL COMPOUND | 2016 |
|
RU2686722C1 |
| NOVEL CRYSTALLINE FORM OF TRIAZOLO(4,5-d)PYRIMIDINE | 2005 |
|
RU2418802C2 |
| ANTITUMOR DRUG FOR INTERMITTENT ADMINISTRATION OF FGFR INHIBITOR | 2014 |
|
RU2664118C2 |
| ANTICANCER THERAPY USING COMPOUNDS OF 3,5-DISUBSTITUTED BENZENE ALKYNYL AND PEMBROLIZUMAB | 2020 |
|
RU2822064C2 |
| CRYSTALLINE FORMS OF FREE BASE | 2014 |
|
RU2675851C2 |
| NEW CRYSTAL AND AMORPHOUS FORM OF TRYAZOL[4,5-d] PYRIMIDINE | 2001 |
|
RU2325391C2 |
